SAN MATEO, Calif. and SINGAPORE, July 15, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (“ASLAN” or the “Company”, Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that on July 9, 2024, the Company was notified by the staff of the Listing Qualifications Department (the 'Staff') of The Nasdaq Stock Market LLC ('Nasdaq') that, based upon the Company’s non-compliance with the $1.00 bid price and $2.5 million stockholders’ equity requirements for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rules 5550(a)(2) and 5550(b)(1), respectively, the Staff had determined to delist the Company’s securities from Nasdaq.

加利福尼亚州圣马特奥和新加坡，2024年7月15日（环球通讯社）--阿斯兰制药公司（“阿斯兰”或“公司”，纳斯达克：ASLN），一家临床阶段，以免疫学为重点的生物制药公司，开发创新治疗方法以改变患者的生活，今天宣布，2024年7月9日，该公司收到纳斯达克股票市场有限责任公司（“纳斯达克”）上市资格部门（“员工”）的通知，根据该公司不符合纳斯达克上市规则5550（a）（2）和5550（b）（1），员工已决定将公司证券从纳斯达克退市。

Upon consideration by the Company’s board of directors, the Company has determined not to request a hearing before the Nasdaq Hearings Panel. As previously disclosed, on January 5, 2024, the Staff notified the Company that the bid price for the Company’s American Depositary Shares (“ADSs”) had closed below the minimum $1.00 threshold for the previous 30 consecutive business days.

经公司董事会审议，公司决定不要求在纳斯达克听证会小组之前举行听证会。如前所述，2024年1月5日，该员工通知该公司，该公司美国存托股（“ADS”）的投标价格在过去30个连续工作日内已低于最低1.00美元的门槛。

In accordance with the Nasdaq Listing Rules, the Company was provided a 180 calendar day period, through July 3, 2024, to regain compliance with the bid price requirement. As also disclosed, on April 18, 2024, the Staff notified the Company that it no longer satisfied the stockholders’ equity requirement of $2.5 million, and the Company was provided with the opportunity to address the deficiency and submit a compliance plan for the Staff’s review, which the Company timely submitted.

根据纳斯达克上市规则，该公司获得了180个日历日的期限，至2024年7月3日，以恢复符合投标价格要求。另外据披露，2024年4月18日，员工通知公司不再满足250万美元的股东权益要求，公司有机会解决缺陷并提交合规计划供员工审查，公司及时提交了合规计划。

As previously disclosed, effective July 3, 2024, the Company changed the ratio of its ordinary shares, par value $0.01 per share, from one (1) ADS representing twenty.

如前所述，自2024年7月3日起，该公司将其普通股（每股面值0.01美元）的比例从一（1）份代表二十（20）份的ADS更改为一（1）份。